Alexza Pharmaceuticals, Inc (ALXA)

  • Alexza Pharmaceuticals, Inc (ALXA)

    Vagnum wrote:

    ALXA 3.50$ , neue Präsentationen sind draussen. nächste Woche an der JPM Konferenz werden sie präsentiert.


    sorry hab nen fehler geschrieben. lol

    nicht JPM sondern Jeffries. :):)

    edit: War schon richtig JPM. :lol:

    oje.. :roll:

  • ALXA 3.50$

    Seit dem 17 September hat sich eine Bullenflagge im ALXA Chart gebildet. Gleichbleibender Preis bei kleinem Verkaufsvolumen. Ein sehr gutes Zeichen vorallem hier oben bei diesem Preis. Sobald hier Volumen reingekickt wird ist ALXA schnell bei 3.90$. Ich vermute sie könnten die 800 Tage Linie bei 4.10$ testen. Nächste Woche am 27. September präsentiert sich die Firma an der JPM (:lol:) Koferenz.

    Dies ist die letzte Präsentation vor dem Zulassungsdatum. Es bleiben noch 11 Handelstage bis zum Termin. Die FDA hat übrigens die Manufacturing Anlage von ALXA inspiziert. Wie die Inspektion verlaufen ist weiss ich nicht genau aber ich bin ein Freund von keine News sind gute News hier mit ALXA. ;)

    allen die dabei sind gutes gelingen. 8)

    [Blocked Image:]

  • Alexza Pharmaceuticals, Inc (ALXA)

    ALXA 3.23$ wird runtergedückt. muss meine aussage evtl rewidieren. wenns so schnell runtergeht. könnte 3$ ein mögliches ziel sein bei der 200 Tage linie.


    mal seh wie wir heute schliessen. 3.30$ wäre wünschenswert.

  • Factbox: Key facts about Biovail and Valeant

    Biovail ist Partner von ALXA für Staccato loxapine.


  • Alexza Pharma (ALXA) Files 376K Common Offering

    schon wieder.. mist :/

    muss mal überlegen ob ich hier nach kaufe.


    Common Stock, $.0001 par value, issuable upon the exercise of a warrant

    376,394 $ 3.30

  • Coming Catalysts for Biotech Stocks During October


    na dann mal sehn...

    ALXA 3.16$

  • Alexza Pharmaceuticals, Inc (ALXA)

    Alexza Could Hit $5 on Approval News

    Alexza Pharmaceuticals, Inc. (ALXA, Free Analysis), a pharmaceutical company focused on commercializing products to treat CNS disorders, could hit $5.00 per share – a 57.7% premium to the current market price – if AZ-004 is approved, according to RBC Capital. The analyst believes the FDA panel was a positive sign and assigned a 65% probability of approval.

    The NDA for the inhalation delivered AZ-004 was originally filed in August of 2005, while the product is being developed to treat agitation in patients with schizophrenia or bi-polar disorder through a partnership with Biovail in the U.S. and Canada. Throughout clinical trials, the drug has demonstrated predictable and consistent safety and efficacy profiles.…-and-recommendations-849/

  • Alexza Pharmaceuticals, Inc (ALXA)

    sharewatch wrote:

    bin im Moment noch drin. nächste Woche dürfte es volatil werden. hmm ALXA ist nicht der Top Pick des Jahres muss entscheiden nächste Woche. dieses Wochenende kommt ein Artikel raus über Risiko vs. Benefit. nach dem werde ich mich richten.

    gruess und schönes weekend. :):)

  • Alexza Pharmaceuticals, Inc (ALXA)

    Das werden spannende und volatile tage hier mit ALXA.

    niemand weiss genau ob sie die Zulassung kriegen werden. mit 60% chancen für eine Zulassung ist das schon ein ziemliches Risiko wenn es doch nicht klappen sollte und der Aktienpreis danach auf unter 2$ flutscht.

    Was denkst du, warum sollte die FDA das Staccato System Zulassen und nicht wie bisher auf Pillen und Injektionen verbleiben? :?: :idea:

  • Alexza Pharmaceuticals, Inc (ALXA)

    Biotech investors should be ready for a big week. With multiple FDA decisions on the line, there should be ample trading and investing opportunities out there. Let's focus on one of these events in particular.

    With a PDUFA date of October 11th (Monday), investors expect to hear news from the FDA regarding Alexza Therapeutics Inc (NASDAQ: ALXA) NDA for loxapine, which utilizes their unique Staccato delivery technology. Approval would certainly validate this approach and reward ALXA investors. If approved, ALXA will receive $15M milestone payment, with an additional $25M if approval in the outpatient setting and $25M at first product shipment. (Note: Approval news could potentially come on Tuesday, given Monday is a federal holiday.)

    We see the sole sole question mark for ALXA to be respiratory safety, considering deep lung delivery of pharmaceutical agents can induce lung inflammation or lung tissue changes. With that said, Loxapine is a small-molecule drug without any cancerogenic or abusive properties. ALXA’s Phase 3 studies confirmed Staccato loxapine was safe and effective, including no serious adverse events. There is a chance the FDA will require a long term lung safety study, however, we believe this to be unlikely given the lack of an advisory panel and the nature of the drugs use.

    Additionally, given this is an 505(b)(2) submission, the regulatory risk is significantly lower. Loxapine has been approved for 30+ years and ALXA's safety studies showed no serious pulmonary effects.

    Management has made it clear they have made every effort to seek the FDA’s opinion on aspects of the AZ-004 program. In the 2Q conference call, CEO Tom King talked extensively about their positive interactions with the FDA. At JMP Securities Conference on Sept. 27, CFO August Moretti reiterated this sentiment.

    “Loxapine is not a drug of abuse and it is a very safe drug. There is no respiratory suppression associated with the drug. There is not a particular safety issue in the outpatient setting....

    The FDA has watched the development of the AZ-004 program. We probably had a total of 15 meetings with the FDA on various clinical programs we have brought forward. They've looked at all the development work, they've looked at all the toxicology work. There's no particular concern that has been raised about the issue of the drug being available for systemic delivery.

    Our technology delivers pure API, and so the lung only sees active pharmaceutical ingredient. It doesn't see any formulation material. Everything the lung sees comes across lung wall and is available in the systemic circulation. So there hasn't been a concern about whether there is anything left in the lung, or the distribution of the drug."

    We also believe that the founder and managements previous track record of success with the FDA is something that should not be overlooked. Dr. Alejandro Zaffaroni(see link), founder of ALXA, has an impressive history of drug approvals and successful acquisitions via big pharma. Additionally, CEO Tom King has a history of success in dealings with the FDA, including approval of Actiq while CEO of Anesta which was acquired by Cephalon.

    With most FDA approvals, an investor has to evaluate a company’s risk-reward profile. There are several scenarios for the price following an FDA decision that an investor should consider. If approved without restrictions, ALXA could easily spike 100-150%($6-6.50), given the milestone payments($40M) and short interest; restrictions on the labeling would dampen any spike. If it is not approved, $1.50-2 might be fair value for ALXA, depending on what the FDA says and their current balance sheet. Recently, RBC assigned a 65% probability of approval with $5 as a target price on approval and see sees downside risk to $1 if not approved. Investors also should consider the possibility that the FDA delays their opinion on the NDA, given the number of FDA decision planned for October. We believe we have outlined the investment thesis for ALXA and the case for approval of AZ-004’s(Staccato(R) loxapine).

  • Alexza Pharmaceuticals, Inc (ALXA)

    Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA


    puhh zum glück hab ich noch geschmissen. :roll:

  • Alexza Pharmaceuticals, Inc (ALXA)

    @ blabla

    die FDA hat das System nicht bewilligt. daten aus der Phase 1 Studie gefallen ihnen nicht und es gibt auch probleme mit der Fabrikation.

    bist du etwa letzte woche nicht raus? :shock: